2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-144399A
    CD33 splicing modulator 1 hydrochloride 2762547-06-6 98%
    CD33 splicing modulator 1 (Compound 1) hydrochloride is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid cell surface receptor known to regulate microglial activity. CD33 splicing modulator 1 hydrochloride increases exon 2 skipping in the cellular mRNA pool and can be used to study neurodegenerative diseases including Alzheimer's disease.
    CD33 splicing modulator 1 hydrochloride
  • HY-144681A
    rel-Ceperognastat 2241514-58-7 98%
    rel-Ceperognastat (rel-LY3372689) (Compound Formula Ic) is a O-GlcNAcase (OGA) inhibitor that can be used to study the neurodegenerative diseases and disorders, such as Alzheimer's disease.
    rel-Ceperognastat
  • HY-145297R
    Flupyrimin (Standard) 1689566-03-7
    Flupyrimin (Standard) is the analytical standard of Flupyrimin. This product is intended for research and analytical applications. Flupyrimin is the antagonist for insect nicotinic acetylcholine receptor (nAChR) that exhibits insecticidal effect by targeting insect nervous system.
    Flupyrimin (Standard)
  • HY-14538S1
    Haloperidol-d4-1 136765-35-0 ≥98.0%
    Haloperidol-d4-1 is deuterium labeled haloperidol, and the latter is a potent dopamine D2 receptor antagonist.
    Haloperidol-d4-1
  • HY-14538S3
    Haloperidol-13C6 98%
    Haloperidol-13C6 is the 13C6 labeled Haloperidol. Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
    Haloperidol-13C6
  • HY-14539S3
    Clozapine-d3 1215691-72-7 98%
    Clozapine-d3 (HF 1854-d3) is deuterium labeled Clozapine. Clozapine (HF 1854) is an antipsychotic used for the research of schizophrenia. Clozapine has high affinity for a number of neuroreceptors. Clozapine is a potent antagonist of dopamine D2 with a Ki of 75 nM. Clozapine inhibits the muscarinic M1 receptor and serotonin 5HT2A receptor with Kis of 9.5 nM and 4 nM, respectively. Clozapine is also a potent and selective agonist at the muscarinic M4 receptor (EC50=11 nM).
    Clozapine-d3
  • HY-14541S2
    Olanzapine-d8 1093380-13-2 98%
    Olanzapine-d8 is a deuterated labeled Olanzapine. Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM). Olanzapine is an atypical antipsychotic.
    Olanzapine-d8
  • HY-14544AS
    Quetiapine-d4 hydrochloride 98%
    Quetiapine-d4 (hydrochloride) (ICI204636-d4 (hydrochloride)) is deuterium labeled Quetiapine. Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects.
    Quetiapine-d4 hydrochloride
  • HY-145454A
    Preclamol 85966-89-8 98%
    Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. Preclamol inhibits the locomotor activity of mice and rats in low doses.
    Preclamol
  • HY-145577A
    Lafadofensine (D-(-)-Mandelic acid) 99.95%
    Lafadofensine D-(-)-Mandelic acid is the monoamines reuptake inhibitor. Lafadofensine D-(-)-Mandelic acid has sufficient effects after short-term administration.
    Lafadofensine (D-(-)-Mandelic acid)
  • HY-145833A
    sEH/AChE-IN-4 2490589-12-1 98%
    sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC50 values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively.
    sEH/AChE-IN-4
  • HY-14605BS
    Rasagiline-13C3 mesylate racemic 1216757-55-9 98%
    Rasagiline-13C3 (mesylate racemic) is a 13C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor. Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Rasagiline-13C3 mesylate racemic
  • HY-14608AR
    L-Glutamic acid monosodium salt (Standard) 142-47-2
    L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases.
    L-Glutamic acid monosodium salt (Standard)
  • HY-14608S6
    L-Glutamic acid-5-13C 81202-00-8 98%
    L-Glutamic acid-5-13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-5-13C
  • HY-14608S9
    L-Glutamic acid-15N,d5 98%
    L-Glutamic acid-15N,d5 is the deuterium and 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-15N,d5
  • HY-146663A
    AChE/BChE-IN-3 hydrochloride 2410992-69-5 98%
    AChE/BChE-IN-3 (BMC-1) hydrochloride is a dual AChE and BChE inhibitor with IC50 values of 6.08 μM and 0.383 μM against electric eel AChE (elAChE) and equine serum BChE (eqBChE), respectively.
    AChE/BChE-IN-3 hydrochloride
  • HY-147059R
    Dieckol (Standard) 88095-77-6
    Buclizine (dihydrochloride) (Standard) is the analytical standard of Buclizine (dihydrochloride). This product is intended for research and analytical applications. Buclizine dihydrochloride is an orally active antihistamine antiallergic compound. Buclizine dihydrochloride is a potent teratogen in the rat and shows anti-tumor activity.
    Dieckol (Standard)
  • HY-147331A
    Oseltamivir acid methyl ester hydrochloride 208720-78-9 98%
    Oseltamivir acid methyl ester hydrochloride is a precursor form of the neuraminidase inhibitor and antiviral oseltamivir acid. Oseltamivir acid methyl ester hydrochloride is converted to oseltamivir acid by carboxylesterase 1 (CES1).
    Oseltamivir acid methyl ester hydrochloride
  • HY-147403S
    Tebideutorexant 1637681-55-0 98%
    Tebideutorexant (JNJ-61393215) is a potent orexin receptor antagonist. Tebideutorexant can be used for insomnia research.
    Tebideutorexant
  • HY-147720A
    γ-Secretase modulator 11 hydrochloride 2434630-30-3 98%
    γ-Secretase modulator 11 hydrochloride (compound 1o) is a potent and orally active γ-secretase modulator with an IC50 of 0.029 µM. γ-Secretase modulator 11 hydrochloride induces a robust reduction in brain Aβ42 levels. γ-Secretase modulator 11 hydrochloride rescues cognitive deficits exhibited by AD model mice. γ-Secretase modulator 11 hydrochloride has the potential for the research of alzheimer's disease.
    γ-Secretase modulator 11 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity